Skip to main content
OpenTrials
Completed

NCT Number: NCT02586883

Bronchial Trans-epithelial Transport in Patients With Idiopathic Multiple Dilations of the Bronchi

The purpose of this study is to identify the abnormalities of bronchial trans-epithelial transport of chloride, sodium and bicarbonate in patients with idiopathic dilations of the bronchi.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year–20 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Necker-Enfants Malades Hospital

Paris, 75015, France

About this study

Dilations of the bronchi happens for one child over 3000. The extended forms may progress to respiratory failure. More than one case over two remains of undetermined cause. If the prototype is the cystic fibrosis, other abnormalities of ionic transport may be the cause of a failure of mucociliary clearance and enhance the idiopathic dilations of the bronchi.

The purpose of this study is to identify the abnormalities of bronchial trans-epithelial transport of chloride, sodium and bicarbonate in patients with idiopathic dilations of the bronchi, in comparison to two others groups of patients (without abnormality of ionic transport/with typical cystic fibrosis).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Common criteria for all patients

  • Age between 2 and 20 years.
  • Patient weighing more than 12kg
  • Patients with a scheduled bronchoscopy under clinical monitoring (assessment of bronchial involvement, local samples for bacteriological and histological examination)
  • Signature of consent by the patient or by the / the holder (s) of parental authority and the investigator
  • Patient affiliated to a social security scheme or entitled
  • Patient with contraception (for woman of childbearing age) Specific criteria for idiopathic bronchiectasis patients Patient with idiopathic bronchiectasis in at least two lobes, diagnosis made after extensive screening of known acquired or congenital causes

Specific criteria for "control" patients without abnormal ion transport

  • Patient Not having bronchiectasis s or any supposed alteration in transepithelial ion transport
  • Patients with fiberoptic bronchoscopy performed for one of the following indications:
  • Pulmonary malformations
  • Laryngeal, tracheal, bronchomalacia
  • Airway compression
  • Interstitial pathology
  • Suspicion of foreign body
  • Suspected tuberculosis Specific criteria for patients with a typical form of cystic f ibrosis (CF) Patient carrying 2 causing mutations in the CFTR gene (according to CFTR2 database; http://www.cftr2.org/mutations_history.php) and sweat test> 60 milliequivalent per liter (mEq/L).

Exclusion criteria

Common criteria for all patients

  • Smoking passive or active
  • Not essential bronchial endoscopy in the clinical follow
  • Extension of bronchoscopy time attributed to the difference in potential bronchial incompatible with the patient's general status
  • Patient pregnant or breast feeding
  • Hypersensitivity or cons known contraindications to health products for measurement of DDP (isoproterenol, Amiloride, ATP)

Specific criteria for idiopathic DDB patients

Presence of other congenital or acquired etiologies of DDB:

  • Typical or atypical cystic fibrosis,
  • Immunodeficiency,
  • Primary ciliary dyskinesia,
  • Abnormal bronchial wall structure (Williams-Campbell syndrome, Mounier-Kuhn, Ehlers-Danlos syndrome, Marfan's disease)
  • Infectious DDBs post
  • Extrinsic or endobronchial obstruction (foreign body, malformation, middle lobe syndrome)
  • Chronic inhalation (GERD, swallowing disorders, gastroesophageal tracheal fistula)
  • Allergic bronchopulmonary aspergillosis,
  • System disease.

Treatment and study plan

bronchial ddp test

Other

bronchial ddp test during endoscopy, nasal smear, bronchial smear

Primary outcomes

  1. Response to isoproterenol in solution without chloride ions during bronchial potential difference test (ΔIsoprotérénol / bronchial).

    Time frame: up to 5 days

    Difference between groups for Level of repolarisation

Secondary outcomes

  1. Response to amiloride during bronchial potential difference test

    Time frame: up to 5 days

    Trans-epithelial transport measured in vivo

  2. trans-epithelial ionic transport in the nasal epithelium (nasal DDP)

    Time frame: up to 5 days

    Trans-epithelial transport measured in vivo

  3. trans-epithelial ionic transport of sweat epithelium (sweat test)

    Time frame: up to 5 days

    Trans-epithelial transport measured in vivo

  4. Basal current short circuit

    Time frame: up to 5 days

    Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures

  5. Response to Epithelial Sodium Channel (ENaC) inhibitors

    Time frame: up to 5 days

    Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures

  6. Activation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)

    Time frame: up to 5 days

    Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures

  7. Inhibition of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) (inh-172)

    Time frame: up to 5 days

    Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures

  8. Activation of Calcium (Ca)-dependent Chloride (Cl-) ion channels

    Time frame: up to 5 days

    Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures

  9. Inhibition of Solute Carrier family 26, member 9 (SLC26A9)

    Time frame: up to 5 days

    Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures

  10. Response to inhibitors of potassium (K+ ) secretion basolateral

    Time frame: up to 5 days

    Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures

  11. Bicarbonate (HCO3- ) secretion in response to forskolin

    Time frame: up to 5 days

    Trans-bronchial epithelial ionic transport evaluated in vitro on bronchial primary cultures

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

Study of the Bronchial Trans-epithelial Transport in Patients With Idiopathic Multiple Dilations of the Bronchi

Acronym: EPITRANS

Important dates

Study start
2016
Primary completion
2020
Study completion
2020
First posted
Oct 27, 2015
Registry last updated
Mar 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.